These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 35050711)

  • 21. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Riera Knorrenschild J; Haag GM; Pohl M; Thuss-Patience P; Bassermann F; Helbig U; Weißinger F; Schnoy E; Becker K; Stocker G; Rüschoff J; Eisenmenger A; Karapanagiotou-Schenkel I; Lordick F
    Eur J Cancer; 2015 Mar; 51(5):569-76. PubMed ID: 25694417
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association between timely targeted treatment and outcomes in patients with metastatic HER2-overexpressing gastroesophageal adenocarcinoma.
    Lau-Min KS; Li Y; Eads JR; Mamtani R; Getz KD
    Cancer; 2022 May; 128(9):1853-1862. PubMed ID: 35119688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
    JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience.
    Maron SB; Moya S; Morano F; Emmett MJ; Chou JF; Sabwa S; Walch H; Peterson B; Schrock AB; Zhang L; Janjigian YY; Chalasani S; Ku GY; Disel U; Enzinger P; Uboha N; Kato S; Yoshino T; Shitara K; Nakamura Y; Saeed A; Kasi PM; Chao J; Lee J; Capanu M; Wainberg Z; Petty R; Pietrantonio F; Klempner SJ; Catenacci DVT
    J Clin Oncol; 2022 Aug; 40(22):2458-2467. PubMed ID: 35349370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
    Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
    Bartley AN; Washington MK; Ventura CB; Ismaila N; Colasacco C; Benson AB; Carrato A; Gulley ML; Jain D; Kakar S; Mackay HJ; Streutker C; Tang L; Troxell M; Ajani JA
    Am J Clin Pathol; 2016 Dec; 146(6):647-669. PubMed ID: 28077399
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ramucirumab in HER-2-positive gastroesophageal adenocarcinoma: an argument for overcoming trastuzumab resistance.
    Tehfe M; Tabchi S; Laterza MM; De Vita F
    Future Oncol; 2018 Feb; 14(3):223-228. PubMed ID: 29318901
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis.
    Ilhan-Mutlu A; Taghizadeh H; Beer A; Dolak W; Ba-Ssalamah A; Schoppmann SF; Hejna M; Birner P; Preusser M
    Cancer Biol Ther; 2018 Mar; 19(3):169-174. PubMed ID: 29252101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The impact of concomitant genomic alterations on treatment outcome for trastuzumab therapy in HER2-positive gastric cancer.
    Lee JY; Hong M; Kim ST; Park SH; Kang WK; Kim KM; Lee J
    Sci Rep; 2015 Mar; 5():9289. PubMed ID: 25786580
    [TBL] [Abstract][Full Text] [Related]  

  • 31. HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib.
    Press MF; Ellis CE; Gagnon RC; Grob TJ; Buyse M; Villalobos I; Liang Z; Wu S; Bang YJ; Qin SK; Chung HC; Xu J; Park JO; Jeziorski K; Afenjar K; Ma Y; Estrada MC; Robinson DM; Scherer SJ; Sauter G; Hecht JR; Slamon DJ
    Mol Cancer Ther; 2017 Jan; 16(1):228-238. PubMed ID: 27811012
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOLFIRINOX for the Treatment of Advanced Gastroesophageal Cancers: A Phase 2 Nonrandomized Clinical Trial.
    Park H; Jin RU; Wang-Gillam A; Suresh R; Rigden C; Amin M; Tan BR; Pedersen KS; Lim KH; Trikalinos NA; Acharya A; Copsey ML; Navo KA; Morton AE; Gao F; Lockhart AC
    JAMA Oncol; 2020 Aug; 6(8):1231-1240. PubMed ID: 32469386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Outcomes of Advanced Gastroesophageal Cancer Patients with Equivocal HER2 Expression with or without ERBB2 Gene Amplification.
    Abdelhakeem A; Wang X; Rogers JE; Trail A; Zhao M; Blum-Murphy M; Estrella JS; Ajani JA
    Oncology; 2020; 98(12):884-888. PubMed ID: 32998149
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ERBB2 amplifications in esophageal adenocarcinoma.
    Dahlberg PS; Jacobson BA; Dahal G; Fink JM; Kratzke RA; Maddaus MA; Ferrin LJ
    Ann Thorac Surg; 2004 Nov; 78(5):1790-800. PubMed ID: 15511476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adherence to and determinants of guideline-recommended biomarker testing and targeted therapy in patients with gastroesophageal adenocarcinoma: Insights from routine practice.
    Lau-Min KS; Li Y; Eads JR; Wang X; Meropol NJ; Mamtani R; Getz KD
    Cancer; 2021 Jul; 127(14):2562-2570. PubMed ID: 33730386
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical outcomes and ctDNA correlates for CAPOX BETR: a phase II trial of capecitabine, oxaliplatin, bevacizumab, trastuzumab in previously untreated advanced HER2+ gastroesophageal adenocarcinoma.
    Singh H; Lowder KE; Kapner K; Kelly RJ; Zheng H; McCleary NJ; Abrams TA; Chan JA; Regan EM; Klempner SJ; Hannigan AM; Remland J; Brais LK; Andrews E; Yurgelun M; Cleary JM; Rubinson DA; Ritterhouse LL; Maron G; Aguirre AJ; Meyerhardt JA; Gardecki E; Lennerz JK; Wolpin BM; Enzinger PC
    Nat Commun; 2024 Aug; 15(1):6833. PubMed ID: 39122726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Wang H; Li B; Liu Z; Gong J; Shao L; Ren J; Niu Y; Bo S; Li Z; Lai Y; Lu S; Gao J; Shen L
    Eur J Cancer; 2018 Jan; 88():92-100. PubMed ID: 29207318
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
    Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
    Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
    [TBL] [Abstract][Full Text] [Related]  

  • 39. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial.
    Janjigian YY; Maron SB; Chatila WK; Millang B; Chavan SS; Alterman C; Chou JF; Segal MF; Simmons MZ; Momtaz P; Shcherba M; Ku GY; Zervoudakis A; Won ES; Kelsen DP; Ilson DH; Nagy RJ; Lanman RB; Ptashkin RN; Donoghue MTA; Capanu M; Taylor BS; Solit DB; Schultz N; Hechtman JF
    Lancet Oncol; 2020 Jun; 21(6):821-831. PubMed ID: 32437664
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extreme chromosome 17 copy number instability is a prognostic factor in patients with gastroesophageal adenocarcinoma: A retrospective cohort study.
    Birkness JE; Spada NG; Miller C; Luketich JD; Nason KS; Sun W; Davison JM
    Genes Chromosomes Cancer; 2018 Jan; 57(1):28-34. PubMed ID: 28913947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.